StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report report published on Wednesday morning. The firm issued a sell rating on the stock.
Ayala Pharmaceuticals Trading Down 4.7 %
Shares of Ayala Pharmaceuticals stock opened at $0.25 on Wednesday. Ayala Pharmaceuticals has a 12 month low of $0.14 and a 12 month high of $1.95. The stock’s fifty day moving average price is $0.41 and its 200-day moving average price is $0.60. The firm has a market cap of $2.69 million, a P/E ratio of -0.03 and a beta of 1.45.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last posted its earnings results on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Further Reading
- Five stocks we like better than Ayala Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- Dividend Payout Ratio Calculator
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
